Melanoma
Melanoma is a malignant neoplasm arising from melanocytes, the pigment-producing cells responsible for melanin synthesis.
Melanoma is a malignant neoplasm arising from melanocytes, the pigment-producing cells responsible for melanin synthesis. It is most commonly associated with the skin, although melanocytic tumors can occur in other anatomical sites, including the nail unit. As a form of skin cancer, melanoma is clinically important because it can invade surrounding tissue and metastasize to regional lymph nodes or distant organs. Its biology involves interactions among tumor cells, the tumor microenvironment, immune cells, and signaling pathways that may include alterations involving BRAF or NRAS.
Melanoma research spans epidemiology, pathology, prognosis, diagnostic imaging, surgery, rehabilitation, targeted drug delivery, and cancer immunotherapy. Therapeutic investigations include checkpoint inhibitors such as nivolumab and ipilimumab, approaches intended to stimulate CD8-positive T-cell or broader T-lymphocyte responses, and experimental systems designed to induce apoptosis or generate reactive oxygen species. The literature represented here is broad rather than centered on a single biological question: it includes population-level burden estimation, clinical cohorts, case reports, perioperative care, artificial-intelligence-assisted diagnosis, and experimental nanotheranostics.
- Molecular Dynamics Simulation-Guided 124I/211At-Labeled Aromatic Amide Derivatives as a Potential Theranostic Pair for Melanoma. PMID 42969691
- Catatonic signs during delirium in leptomeningeal melanoma: Treatment trade-offs in end-of-life care. PMID 42972997
Where the papers sit
14 papers from the last 6 months study melanoma directly
Study type 1 clinical trial · 4 observational · 2 human data · 6 preclinical · 1 unclassified
Themes one subject · 1 new direction
Those 14 are all about one subject.
-
Melanoma Care and Outcomes
Melanoma research spans treatment, prognosis, survivorship, and population burden from early disease through metastatic and end-of-life care. Clinical studies address delayed recurrence, hospital immunotherapy volume, perioperative rehabilitation, delirium, and outcomes in elderly populations. Translational work explores PD-1-positive mast cells, cancer stemness, immune microenvironments, radionuclide theranostics, photodynamic therapy, topical delivery, and resiquimod with anti-PD-1 therapy. No single therapeutic direction dominates, but improved risk assessment, immune treatment, targeted delivery, and supportive care recur across the field.
Leptomeningeal melanoma is presented as a neurological cause of catatonia–delirium requiring symptom-directed end-of-life management
The case of advanced leptomeningeal melanoma departs from the set’s predominant roles for melanoma as a tumor target, prognostic condition, epidemiologic burden, or immune-biologic model by treating it as the setting for fluctuating catatonic and delirious signs. The patient’s catatonic signs transiently improved with lorazepam but functional recovery did not follow, while agitation and safety concerns led to discontinuation of lorazepam and introduction of haloperidol. This shifts the practical focus from controlling melanoma or predicting its course to balancing diagnostic uncertainty, sedation, agitation, and comfort during hospice transition 42972997Nov.
Papers
The 14 papers from the last 6 months that study melanoma directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Melanoma Care and Outcomes (14)
- Catatonic signs during delirium in leptomeningeal melanoma: Treatment trade-offs in end-of-life care. Palliative & supportive care · 3 Nov 2026 PMID 42972997
- Molecular Dynamics Simulation-Guided 124I/211At-Labeled Aromatic Amide Derivatives as a Potential Theranostic Pair for Melanoma. Molecular pharmaceutics · 2 Nov 2026 PMID 42969691
- Investigating Risk Factors for Delayed Melanoma Recurrence Beyond 5 Years Post-Primary Tumor Diagnosis. Cancer medicine · 29 Oct 2026 PMID 42952107
- Mast cell phenotypic remodeling toward a PD-1-positive, Chymase-negative phenotype is associated with metastatic melanoma and poor survival. Oncoimmunology · 23 Oct 2026 PMID 42912494
- Cutaneous melanoma and JAK inhibitors: a disproportionality analysis in EudraVigilance. European journal of clinical pharmacology · 13 Oct 2026 PMID 42870108
- Deciphering the crosstalk between cancer stemness and the immune microenvironment in melanoma: a single-cell transcriptomic analysis. Dermatology (Basel, Switzerland) · 12 Oct 2026 PMID 42862771
- The Relationship Between Hospital Immunotherapy Volume and Treatment and Survival of Advanced Cutaneous Melanoma. The Journal of surgical research · 2 Oct 2026 PMID 42826672
- Burden of malignant melanoma among the elderly population in East Asia from 1990 to 2023 and machine learning projection to 2040. PloS one · 11 Sept 2026 PMID 42727032
- Clinicopathological characteristics and prognosis of melanoma: A retrospective cohort study in Xinjiang, China. PloS one · 9 Sept 2026 PMID 42715204
- A Coordinated Approach to Perioperative Rehabilitation to Enhance Outcomes in Melanoma: Protocol for the CARE-Melanoma Pilot Randomized Controlled Trial. JMIR research protocols · 21 Aug 2026 PMID 42628027
- Pluronic F127 engineered nanotheranostics for NIR-II fluorescence imaging and enhanced photodynamic therapy in melanoma. Journal of materials chemistry. B · 30 Jul 2026 PMID 42530322
- L-Dopa-asparagine-derived carbon dots as a targeted theranostic agent for melanoma. Chemical communications (Cambridge, England) · 28 Jul 2026 PMID 42517688
- QbD-engineered EGCG-rosmarinic acid cubosomal hydrogel for controlled skin delivery and antimelanoma efficacy. International journal of pharmaceutics · 25 Jul 2026 PMID 42501769
- Topical Resiquimod Elicits Systemic Protection and Improves Anti-PD-1 Therapy in Melanoma via Priming of CD8+ T Cells. Cancer immunology research · 11 Jun 2026 PMID 42275481
By study type
Clinical trials (1)
- A Coordinated Approach to Perioperative Rehabilitation to Enhance Outcomes in Melanoma: Protocol for the CARE-Melanoma Pilot Randomized Controlled Trial. JMIR research protocols · 21 Aug 2026 PMID 42628027
Observational studies and case reports (4)
- Catatonic signs during delirium in leptomeningeal melanoma: Treatment trade-offs in end-of-life care. Palliative & supportive care · 3 Nov 2026 PMID 42972997
- Investigating Risk Factors for Delayed Melanoma Recurrence Beyond 5 Years Post-Primary Tumor Diagnosis. Cancer medicine · 29 Oct 2026 PMID 42952107
- The Relationship Between Hospital Immunotherapy Volume and Treatment and Survival of Advanced Cutaneous Melanoma. The Journal of surgical research · 2 Oct 2026 PMID 42826672
- Clinicopathological characteristics and prognosis of melanoma: A retrospective cohort study in Xinjiang, China. PloS one · 9 Sept 2026 PMID 42715204
Human data, design not indexed (2)
- Cutaneous melanoma and JAK inhibitors: a disproportionality analysis in EudraVigilance. European journal of clinical pharmacology · 13 Oct 2026 PMID 42870108
- Burden of malignant melanoma among the elderly population in East Asia from 1990 to 2023 and machine learning projection to 2040. PloS one · 11 Sept 2026 PMID 42727032
Preclinical: animal, cell and lab studies (6)
- Molecular Dynamics Simulation-Guided 124I/211At-Labeled Aromatic Amide Derivatives as a Potential Theranostic Pair for Melanoma. Molecular pharmaceutics · 2 Nov 2026 PMID 42969691
- Mast cell phenotypic remodeling toward a PD-1-positive, Chymase-negative phenotype is associated with metastatic melanoma and poor survival. Oncoimmunology · 23 Oct 2026 PMID 42912494
- Pluronic F127 engineered nanotheranostics for NIR-II fluorescence imaging and enhanced photodynamic therapy in melanoma. Journal of materials chemistry. B · 30 Jul 2026 PMID 42530322
- L-Dopa-asparagine-derived carbon dots as a targeted theranostic agent for melanoma. Chemical communications (Cambridge, England) · 28 Jul 2026 PMID 42517688
- QbD-engineered EGCG-rosmarinic acid cubosomal hydrogel for controlled skin delivery and antimelanoma efficacy. International journal of pharmaceutics · 25 Jul 2026 PMID 42501769
- Topical Resiquimod Elicits Systemic Protection and Improves Anti-PD-1 Therapy in Melanoma via Priming of CD8+ T Cells. Cancer immunology research · 11 Jun 2026 PMID 42275481
Unclassified: not yet indexed with MeSH (1)
- Deciphering the crosstalk between cancer stemness and the immune microenvironment in melanoma: a single-cell transcriptomic analysis. Dermatology (Basel, Switzerland) · 12 Oct 2026 PMID 42862771
Written from 14 PubMed abstracts, each one listed by PMID above. Published: 2026-09-13. Drafted by language models from published abstracts; not medical advice.